口服5-阿扎胞苷联合罗米地辛在PTCL中显示显著活性:一项多中心1期研究
外周T细胞淋巴瘤(PTCL)对表观遗传修饰剂敏感。基于临床前模型,开展1期研究,口服5-阿扎胞苷联合罗米地辛治疗晚期淋巴系统恶性肿瘤,最大耐受剂量为AZA 300mg d1-14联合ROMI 14mg/m2 d8,15,22(35天周期),常见剂量限制性毒性为血小板减少和中性粒细胞减少。在PTCL患者中总反应率达73%,完全缓解率55%,显著高于非T细胞淋巴瘤。
要点
- PTCL患者ORR 73%、CR 55%,非T细胞淋巴瘤ORR 10%、CR 5%。
- 最大耐受剂量:AZA 300mg d1-14,ROMI 14mg/m2 d8、15、22,35天周期。
- 主要剂量限制性毒性为4级血小板减少、延长性3级血小板减少、4级中性粒细胞减少和胸腔积液。
核心结论
- 联合表观遗传修饰剂在PTCL患者中具有强效活性,且耐受性可管理。
研究设计与样本
- 多中心1期研究,采用3+3设计,共治疗31例晚期淋巴系统恶性肿瘤患者。
主要发现
- PTCL患者ORR 73%、CR 55%,非T细胞淋巴瘤患者ORR 10%、CR 5%。
- 总体、非T细胞和T细胞淋巴瘤患者的ORR分别为32%、10%和73%,CR率分别为23%、5%和55%。
- 未发现缓解与去甲基化水平或肿瘤突变谱相关。
关键数值与推荐
- 最大耐受剂量为AZA 300mg d1-14联合ROMI 14mg/m2 d8、15、22,35天周期。
- 剂量限制性毒性包括4级血小板减少、延长性3级血小板减少、4级中性粒细胞减少和胸腔积液。
- 未发生治疗相关死亡。
临床怎么用
- 该联合方案可作为PTCL患者的一种潜在治疗选择,需进一步研究验证。
局限性
- 1期研究样本量小,需更大规模研究确认疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The peripheral T-cell lymphomas (PTCLs) are uniquely sensitive to epigenetic modifiers. Based on the synergism between histone deacetylase inhibitors and hypomethylating agents that we established in preclinical PTCL models, we conducted a phase 1 study of oral 5-azacytidine (AZA) and romidepsin (ROMI) in patients with advanced lymphoid malignancies, with emphasis on PTCL. According to a 3 + 3 design, patients were assigned to 1 of 7 cohorts with AZA doses ranging from 100 mg daily on days 1 to 14 to 300 mg daily on days 1 to 21, ROMI doses ranging from 10 mg/m2 on days 8 and 15 to 14 mg/m2 on days 8, 15, and 22, with cycles of 21 to 35 days. Coprimary end points included maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). We treated a total of 31 patients. The MTD was AZA 300 mg on days 1 to 14 and ROMI 14 mg/m2 on days 8, 15, and 22 on a 35-day cycle. DLTs included grade 4 thrombocytopenia, prolonged grade 3 thrombocytopenia, grade 4 neutropenia, and pleural effusion. There were no treatment-related deaths. The combination was substantially more active in patients with PTCL than in those with non-T-cell lymphoma. The overall response rate in all, non-T-cell, and T-cell lymphoma patients was 32%, 10%, and 73%, respectively, and the complete response rates were 23%, 5%, and 55%, respectively. We did not find an association between response and level of demethylation or tumor mutational profile. This study establishes that combined epigenetic modifiers are potently active in PTCL patients. This trial was registered at www.clinicaltrials.gov as NCT01998035.
引用
- O'Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019. PMID: 31471376. doi:10.1182/blood.2019001285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。